

Witness Name: Karen Phillips

Statement No.: WITN3214001

Exhibits: WITN3214002– WIT3214010

Dated: 9 October 2019

THE INFECTED BLOOD INQUIRY

EXHIBIT WITN3214007

University Hospital Birmingham

The Queen Elizabeth Hospital
Edgbaston
Birmingham
B15 2TH

West Midlands Adult Comprehensive Care Haemophilia Centre
3rd Floor (Purple Zone) Queen Elizabeth Hospital
Dr Jonathan Wilde MD, FRCP, FRCPath. E-Mail: GRO-C
Haemophilia Unit Tel: (0121) 627 2353 Fax: (0121) 697 8497
Dr Wilde's secretary Tel: (0121) 472 1311 extension GRO-C

Tel: 0121 472 1311

20th September 2004

Dear Doctor.....*Gate*.....

Variant Creutzfeldt-Jakob Disease (vCJD) and Plasma Products

You may be aware that an exercise is underway to trace and inform patients who have received batches of British clotting factor concentrate between 1980 & 2001 which may have exposed them to vCJD. These individuals are considered to be "at-risk" for public health purposes.

The Health Protection Agency's Communicable Disease Surveillance Centre (Colindale) is handling the patient notification in England, Wales and Northern Ireland. The Scottish Centre for Infection and Environmental Health is handling this notification in Scotland.

I am writing to inform you that your patient*Kwame Nwagwu (16/10/03)*..... falls into the "at-risk" group of patients who are being asked to take special precautions to reduce any possible risk of further transmission of vCJD.

Your patient has been asked:

- not to donate blood, tissues or organs
- to inform people providing their medical, surgical or dental treatment so any special procedures recommended for the instruments used in their care can be arranged, and to consider informing their family in case emergency surgery is needed in the future.

As part of these public health measures I should be grateful if you would:

- record the patient's vCJD 'at-risk' status and the special precautions required in their primary care record,
- include this information in any referral letters should the patient require certain surgery or other invasive medical procedures (guidance on infection control for any patient who is considered 'at-risk' of vCJD was published by the ACDP TSE Working Group in 2003: <http://www.advisorybodies.doh.gov.uk/acdp/tseguidance/Index.htm>)

vCJD and Plasma Products – Letter to patients' GPs
[Date]

1

- check if the patient has undergone any surgery within the past 12 months at other hospitals. If they have, please liaise with your local Health Protection Team in order to ascertain whether any further action needs to be taken.

Being identified as 'at-risk' for public health purposes should not compromise the clinical care your patient receives in any way. However you may wish to consider your patient's 'at-risk' status should they develop symptoms indicative of vCJD.

If you require any further information about this situation then please refer to the following websites:

Health Protection Agency: http://www.hpa.org.uk/infections/topics_az/cjd/menu.htm

National CJD Surveillance Unit: <http://www.cjd.ed.ac.uk>

Yours sincerely

GRO-C

Jonathan Wilde
Consultant Haematologist
Haemophilia Centre Director